IL3, interleukin 3, 3562

N. diseases: 211; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 Biomarker disease BEFREE Hence, we developed a novel strategy that combines both essential signals in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells. c-MPL signaling activates pathways shared with conventional costimulatory and cytokine receptor signaling. 29079582 2017
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 Biomarker disease BEFREE Herein, we examined macrophages for their functions and responsiveness to IL-3 and GM-CSF in ENU-induced leukemia in BALB/c mice. 28039843 2017
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 Biomarker disease BEFREE We found that the IL-3 receptor-α (IL-3Rα) is a promising candidate as an leukemia-initiating cell-specific antigen for FA-AML. 21330473 2011
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 AlteredExpression disease BEFREE Our results indicated that (1) the expression of TEL-FGFR3 but not DeltaHLH-TEL-FGFR3 resulted in efficient focus formation in NIH/3T3 cells and conferred interleukin 3 independence to Ba/F3 cells by a constitutive tyrosine kinase activity probably through oligomerization by the HLH domain of TEL; (2) although effector proteins including classical mitogen-activated protein kinase (MAPK), p38 MAPK, phosphatidylinositol 3-kinase (PI3-K), mammalian target or rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT-3) and STAT-5 were activated in TEL-FGFR3 transformants, the growth of the transformants was inhibited by SU5402 (concentration that inhibits 50% [IC5)]=5 microM) and the PI3-K inhibitor, LY294002 (IC5)=10 microM) and wortmannin (IC50=5 microM), but not by U0126, SB203580, or rapamycin; and (3) injection of TEL-FGFR3 transformants induced lethal leukemia into syngeneic mice. 15514005 2005
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 Biomarker disease BEFREE These data indicate that transgenic SCID mice expressing human IL-3 and GM-CSF provide a useful system for the study of human leukemia. 9714520 1998
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 AlteredExpression disease BEFREE Deregulation of IL-3 receptor chain gene expression may provide a proliferative advantage to hematopoietic cells growing under conditions in which the cytokine is limiting and allow the development of a leukemia. 8642872 1996
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 Biomarker disease BEFREE Bone marrow cells were studied prior to and after 3 days of IL-3 administration to assess changes in overall and leukemic progenitor cell [leukemia colony-forming unit (CFU-L)] proliferation, and progenitor cell sensitivity to 1-betad-arabinofuranosylcytosine. 9815985 1995
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 GeneticVariation disease BEFREE Our data support the formulation that this subtype of leukemia may arise in part because of a chromosome translocation that activates the IL-3 gene, resulting in autocrine and paracrine growth effects. 2114933 1990
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.090 Biomarker disease BEFREE The data suggest that activation of the IL-3 gene by the enhancer of the immunoglobulin heavy chain gene may play a central role in the pathogenesis of this leukemia and the associated eosinophilia. 2499362 1989